display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-177

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons